The History of Cardiovascular Magnetic Resonance  by Pohost, Gerald M.
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nhe most beautiful experience we can have is the
ysterious. It is the fundamental emotion that stands
t the cradle of true art and true science . . .
Albert Einstein (1)
ardiovascular magnetic resonance (CMR) has
eveloped progressively during the past 3 de-
ades. It began in the 1970s as a means for
ssessing high-energy phosphate myocardial
etabolism in vitro with 31P spectroscopy to
easure adenosine triphosphate, phosphocre-
tine, and inorganic phosphate in isolated,
erfused, rat hearts (2,3). It progressed in the
980s with clinical imaging to assess cardiac
orphology and function and to characterize
yocardium (e.g., myocardial edema) using the
roton (hydrogen) relaxation properties T1 and
2. Next, with the development of clinically
pplicable paramagnetic contrast agents, it was
pplied to the assessment of myocardial perfu-
ion and the vasculature in the early 1990s and
o the assessment of viability with the detection
f myocardial scar in the 1990s and early
000s. In addition, it was applied to the assess-
ent of the vasculature, including the aorta
nd the peripheral and coronary arteries. Inter-
stingly, it came full circle with the develop-
ent and application of clinical methods to
ssess myocardial metabolism.
rom the Keck School of Medicine; Viterbi School of Engineering,
niversity of Southern Calfornia; and Loma Linda School of
edicine Loma Linda University, Los Angeles, California.ianuscript received July 1, 2008; accepted July 14, 2008.It is the single technology that can be used to
ssess ventricular function, cardiac morphol-
gy, the vasculature, perfusion, viability, and
etabolism, the so-called comprehensive car-
iac examination—or, as I introduced in one of
he initial talks to the Society of Magnetic
esonance in Medicine (SMRM) (which the
uthor was instrumental in starting in 1982),
he “one-stop-shop for cardiac imaging.” All of
his imaging was possible by using the princi-
les of magnetic resonance without the need
or ionizing radiation and with high resolution
n 3 dimensions.
he NMR Phenomenon: Felix Bloch and
dwin Purcell (Nobel Laureates, 1946)
agnetic resonance imaging (MRI), and the
Nobel Prize discoveries important in its
evelopment, evolved with the elucidation of
he phenomenon in liquids and solids known
s nuclear magnetic resonance (NMR), the
evelopment of NMR spectroscopy, and the
iscovery of the approaches that made it
ossible to image (NMR imaging, now
nown as MRI). Felix Bloch at Stanford on
he west coast and Edwin Purcell at Harvard
n the east coast discovered and indepen-
ently reported the phenomenon of NMR in
he same year—1946. For this discovery,
oth Bloch and Purcell received the Nobel
rize in Physics in 1952.
In brief, when a substance containing the
uclei of certain isotopes with magnetic polar-
ty due to spin (examples of biologically rele-
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673ant nuclei are hydrogen, hydrogen-1 or 1H; car-
on-13; fluorine-19; sodium-23; and phosphorus-
1) was placed in a relatively high magnetic field
B) the Larmor equation indicated the frequency of
he radio waves () that were absorbed by the nuclei
o induce resonance:
B
he gyromagnetic ratio () is constant for each
pecific nucleus. The resultant resonance fre-
uency allowed determination of the specific
ucleus.
he Basis for NMR Spectroscopy: Richard Ernst
Nobel Laureate, 1966)
n 1991, Richard Ernst, PhD, received the Nobel
rize for his 1966 work in which he demonstrated
hat it was possible to substantially improve the
ensitivity for generating NMR spectra from sam-
les of inorganic, organic, and ultimately biological
aterials by applying the mathematical operation,
he Fourier transformation to NMR. With these
Figure 1. 31P In Vivo Myocardial Spectra in Two Women With N
31P in vivo myocardial spectra in 2 women with no evidence of sig
an abnormal reduction in PCr/ATP with handgrip stress testing and
grip stress. Such ﬁndings suggestive of myocardial ischemia might
cardium (4). Spectroscopy performed in the year 2000, Heewon Kim
PCr/ATP  phosphocreatine/adenosine triphosphate.iscoveries, Ernst provided the platform for devel- wpment, the higher speed, and more efficient per-
ormance of NMR spectroscopy.
MR Spectroscopy Applied to the Heart
mong the earliest NMR studies applied to the
eart was 31P NMR spectroscopy. Unfortunately,
he term “NMR” has been truncated to the less-
recise term, that of magnetic resonance (MR). In
rief, at a given high magnetic field (e.g., 8.4T), the
adiofrequency energy at the Larmor frequency is
bsorbed and released to and from the hydrogen
uclei of an isolated perfused rat heart. Resultant
adiofrequency signal output is subjected to the
athematical operation—Fourier transformation as
er the approach of Ernst. This step converts the
eleased energy in the time domain (K space) into
he spatial domain (a spectrum) (Fig. 1) (4). The
eaks contained in the spectrum represent different
uclear species within a molecule. In this case, there
re 3 peaks for ATP (one each for the gamma,
lpha, and beta phosphates of ATP), for phospho-
reatine (PCr), and for several phosphorus-
ontaining molecules in the inorganic phosphate
egion of the spectrum (including 2, 3 diphospho-
lycerate in red blood cells and inorganic phosphate
vidence of Signiﬁcant Angiographic Coronary Disease
ant angiographic coronary artery disease yet one (upper row) has
other (lower row) has a normal response in PCr/ATP with hand-
ate the presence of microvascular dysfunction within the myo-
D, Keck School of Medicine, University of Southern California.o E
niﬁc
the
indic
, Phithin muscle and other tissues).
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674MR Imaging: Paul Lauterbur andPeterMansfield
Nobel Laureates, 2003)
n the early 1970s, both Paul Lauterbur, PhD, and
eter Mansfield, PhD, discovered the basis for
MR imaging. When one adds an additional,
mall magnetic field spatial gradient to the spec-
rometer, the variations in resonance induced
ithin the sample interrogated were different from
oint to point. This addition provided a means to
enerate an image. Lauterbur called this approach
he imaginative term “zeugmatography.” Zeugma is
Greek-derived term, meaning to combine 2 com-
onents. In this case, he was referring to the
eneration of images by combining 2 energy
ources, magnetic fields and radiofrequency. The
ddition of orthogonal magnetic field gradients
llowed images (i.e., “...tography”) to be generated.
ansfield provided the basis for the generation of
mages at high-speed imaging, which he termed
echo-planar” imaging. Accordingly, Mansfield had
profound impact on the utility of NMR imaging
zeugmatography) for cardiovascular applications.
auterbur and Mansfield received the Nobel Prize
n Medicine and Physiology in 2003.
arly NMR Imaging
uclear MRI was performed in several physics
aboratories, including those of Lauterbur, Mans-
eld, and Raymond Andrew. Interestingly, sub-
tantial independent imaging development took
lace in both the Mansfield and Andrew laborato-
ies at the University of Nottingham in the United
ingdom. The first laboratories for medical NMR
maging included the laboratories at the University
f California in San Francisco; in the Department
f Radiology headed by Alexander Margulis, MD.
he principal group of scientists included Leon
aufman and Lawrence E. Crookes, at the Univer-
ity of Aberdeen in Scotland in the laboratory of
ohn Mallard, PhD; and at the Massachusetts
eneral Hospital in a multidepartimental labora-
ory under the aegis of this author. Clinical MRI
ere in part outgrowths of the activities of this
aboratory.
MR Imaging in Boston
mong the earliest seeds for the development of the
eld of CMR occurred at the Massachusetts Gen-
ral Hospital (MGH) in approximately 1980. Here
collaboration was initiated between Joanne S.
ngwall, PhD, and Gerald M. Pohost, MD. Ing- Nall, a widely recognized and highly respected
ardiac cell biologist, was recruited to set up a
aboratory at the Peter Bent Brigham Hospital in
he late 1970s. The collaboration started with the
ssessment of Thallium-201, the radionuclide myo-
ardial perfusion imaging agent. Ionic thallium
hloride had interesting and clinically relevant
roperties. They were awarded a National Institutes
f Health (NIH) research grant (R01) to study the
echanism of thallium redistribution. A key com-
onent was to determine the relationship between
hallium uptake and viability. Ingwall used perfu-
ion independent isolated fetal mouse hearts in cell
ulture to assess the relationship between thallium
ptake and cell death. The results as published in a
anuscript (5) suggested that thallium uptake was
elated to the amount of viable myocardium. The
mount of lactic dehydrogenase (LDH) released
nto the culture medium was used as the marker to
uantify the amount of myocardial cell death. Vir-
ually simultaneously, Ingwall was working at the
rancis Bitter National Magnet Laboratory at the
assachusetts Institute of Technology using a 270-
Hz NMR spectrometer to study myocardial
hosphate metabolism in an isolated perfused Lan-
endorff rat heart model. Coupled with the work of
auterbur, Ingwall predicted a potential clinical
uture in the imaging of the distribution of ATP
nd phosphocreatine in the myocardium to deter-
ine the distribution and extent of myocardial
schemia and viability. Ingwall’s enthusiasm for
MR spectroscopy and her studies of myocardial
hosphate metabolism were among the most im-
ortant factors influencing the author’s early inter-
st in NMR. Subsequently, a collaboration was
nitiated in the late 1970s to include Eric Fossel,
hD, an NMR spectroscopist, and Mark Goldman,
D, a cardiologist at the MGH, Ingwall and
ohost. This collaboration resulted in an initial
rticle predicting many of the present day clinical
pplications of NMR to the study of cardiovascular
isease (6).
It was clear that an essential component to the
evelopment of a program in NMR imaging was
he recruitment of an expert NMR physicist, as well
s new instrumentation and funding. We went to
he UK and visited the laboratories of Andrew and
ne of his principal students, Waldo Hinshaw,
hD. Ultimately, we attended the British Society of
MR meeting in York, England. Hinshaw, Ing-
all, Fossel, Goldman, and Pohost presented their
erspective on the future clinical applications of
MR at the headquarters of Johnson and Johnson.
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675ohnson and Johnson soon acquired the imaging
nstrumentation company Technicare (Solon,
hio)—subsequently, Dr. Hinshaw moved to
echnicare; Johnson and Johnson funded the
GH team; and Technicare provided the group
ith 2 new NMR imaging devices: one with a
.44T, 8-cm bore, superconducting magnet, and
he second with a 0.15T, 40-cm bore resistive
agnet. The small-bore system was to be used for
aboratory-type studies, whereas the larger-bore
ystem was used for both laboratory and clinical
euroimaging.
The team at the MGH continued to expand with
he development of a multidisciplinary group in-
luding Ian Pykett, PhD, an imaging physicist from
he Peter Mansfield group in Nottingham, UK;
. Phillip Kistler, MD, a neurologist who special-
zed in stroke; Jeffrey Newhouse, MD, a radiologist
ith interest in x-ray computed tomography;
homas Brady, MD, a nuclear medicine physician,
ecruited as a fellow from the University of Mich-
gan; C. Tyler Burt, PhD, an established NMR
pectroscopist; Ferdi Buonano, MD, a neurologist
ith an interest in imaging; and Bruce Rosen, MD,
 student and then resident in radiology. The
arliest studies from the MGH NMR imaging
aboratory demonstrated that cerebral infarction
ould be clearly delineated in laboratory animal
odels of ischemic stroke using the 0.15T (restive
agnet) platform (7,8). In another study the re-
arkable tugging effects of NMR imaging on a
erromagnetic aneurysm clip in a laboratory animal
as demonstrated (9).
Early cardiac imaging studies emphasized the
nterest of the author in myocardial perfusion
Figure 2. In Vitro NMR Perfusion Images of Canine Heart With L
Paramagnetic MnCl2 was administered in vivo soon after the occlus
infarction. This is among the ﬁrst cardiac NMR studies to be publish
anterior descending artery; NMR  nuclear magnetic resonance; TTmaging (10). The first cardiac high resolution TMR imaging study to be published used the
ntravenous administration of paramagnetic
nCl2 (as originally suggested by Lauterbur)
ntravenously injected in a laboratory animal with
 left anterior descending coronary ligation (Fig.
). It was known from radionuclide studies with
2mMn that manganese ion was deposited in the
yocardium. The hearts were imaged in the
mall-bore, higher-field magnet with an SSFP
ulse sequence. The time of repetition was 7.3 m;
lice thickness was 3 mm; slice acquisition time
as 2.3 min; images were acquired using a 256 
56 matrix interpolated to 512  512. Images
emonstrated myocardial perfusion deficits with
xquisite detail. The heart was then stained with
he supravital dye triphenyltetrazolium chloride.
hen we considered the volume of infarction,
he correlation between NMR and triphenyltet-
azolium chloride was r  0.94. On a slice-by-
lice basis, the correlation was r  0.93.
NMR was clearly gaining scientific momentum,
s it was highlighted in a Disease-a-Month volume
n NMR imaging (11). A review group for the
merican Medical Association (AMA) chaired by
he author wrote a series of articles on NMR for the
arious organ systems imaging for the Journal of the
merican Medical Association (12).
maging and Spectroscopy Between Boston
nd Birmingham
ne of the interesting aspects of NMR is the
iophysical properties that one could image.
hey included the relaxation properties T1 (spin
attice relaxation) and T2 (spin spin relaxation).
Occlusion at 1.44T (Lower Row of Short-Axis Images)
For comparison, TTC staining was used to identify the territory of
Reproduced with permission from Goldman et al. (11). LAD  left
triphenyltetrazolium chloride.AD
ion.
ed.he Sarnoff Foundation provided funding to
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676ngage medical students in a personalized re-
earch experience with respected cardiovascular
cientists. Adam Ratner and Robert Canby were
such highly productive fellows.
Adam Ratner was involved in studies in which
maging of T1 and T2 was used to assess the
everity of a myocardial ischemic insult. It ap-
eared that these parameters would increase
hen the laboratory animal was subjected to a
yocardial ischemic insult and that this increase
as in part due to myocardial edema. In one such
tudy, published in Circulation (13), changes in
I and T2 were compared with myocardial per-
usion in dogs both with and after coronary artery
cclusion. In the occlusion model, there was an
nverse relationship between the relaxation times
nd flow. In the reperfusion model, there was a
elationship between T1 and T2 and flow during
he period of reperfusion. The results suggested
hat the proton relaxation times corresponded to
he severity of an ischemic insult. It was con-
luded that because the use of NMR imaging
ould display differences in relaxation times, im-
ging could provide a means to assess noninva-
ively the severity of the myocardial ischemic
nsult.
Canby et al. (14) were responsible for a study
ublished in the Journal of the American College of
ardiology in which they demonstrated that the
1P NMR spectroscopy-determined phosphocre-
tine/adenosine triphosphate ratio was inversely
elated to the severity of histologically demon-
trated cardiac allograft rejection in a rat model.
his relationship suggested that in vivo31P NMR
pectroscopy might be useful for detecting and
ssessing the severity of cardiac rejection. There
ere many distinguished collaborators in my
MR program at the University of Alabama at
irmingham. They included (in alphabetical or-
er): Alain Bouchard, MD (cardiologist); James
alschi, PhD (spectroscopist); Halima Benjel-
oun, MD (cardiologist); Vera Bittner, MD (car-
iologist); John Chatham, PhD (spectroscopist);
reg Cranney, MD (cardiologist); Mark Doyle
physicist); Lou Dell’Italia, MD (cardiologist);
abriel Elgavish, PhD (lanthanide chemist); Bill
vanochko, PhD (spectroscopist); John Forder,
hD; Hoby Hetherington, PhD; Jan den Hol-
ander, PhD; Lynne Johnson, MD (nuclear car-
iologist); Ruben Kuzniecky, MD (neurologist);
T Lim, MD (cardiologist); Chaim Lotan, MDcardiologist); Tetsuya Matsuda (cardiologist); (eannie McMillin, PhD (cardiac biochemist);
ulie Pan, MD, PhD (neurologist); Martin Pike,
hD (spectroscopist); Russell Reeves, MD (car-
iologist); Don Twieg, PhD (biomedical engi-
eer); and Paul Wolkowicz, PhD (cardiac
iochemist).
he New Societies: SMRM Then International
ociety for Magnetic Resonance in Medicine
ISMRM), the Society of Cardiovascular
agnetic Resonance
he Society of Magnetic Resonance in Medicine. It
as clear that NMR was going to become an
mportant research and clinical tool. I thought that
t would be useful to start a multidisciplinary
cientific/clinical society dedicated to new develop-
ents in NMR and to education. Dr. Ingwall was
lso very much in favor of such a society. Although
he did not participate in the Society’s organization
t that time, she became its president at a later
ate. The first step was to organize an Executive
ommittee. Accordingly, we created a 5-person
xecutive Committee. Tom Budinger, MD, PhD,
as an ideal person to catalyze the formation and
rowth of this new Society. He was a professor in
he Department of Electrical Engineering and
omputer Sciences, University of California,
erkeley, and, a key member of the Lawrence
erkeley National Laboratory. He had a great
nterest in NMR and had made substantial contri-
utions to the field of positron emission tomogra-
hy and NMR. Tom enthusiastically agreed with
he formation of this Society and with the other
embers of the Executive Committee. Dr. Lauter-
ur also thought it was a great idea and we thought
t most appropriate that he be the Society’s first
resident. I agreed to take the position of
ecretary/Treasurer.
The other 2 members of the Executive Com-
ittee included Britton Chance, PhD, a pioneer
n biophysical science at the University of Penn-
ylvania and Alex Margulies, MD, the head of
ne of the most advanced radiology departments
n the world—the University of California at San
rancisco. The first job of the Executive Com-
ittee was to determine how many and who
hould be members of the initial Board of Trust-
es. Finally, the Journal, the Journal of Magnetic
esonance in Medicine, needed to be started. In
ddition to Mansfield, who we recruited, the rest
f the Board included: David Hoult, PhD,
NMR physicist); Seymour Koenig, PhD (NMR
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677hysicist, paramagnetics); John Mallard, PhD;
eorge Radda, PhD (in vivo NMR spectrosco-
ist); Robert Schulman, PhD (Yale spectrosco-
ist); Katherine Scott, PhD (NMR spectro-
copist); Harold Swartz, PhD (electron spin res-
nance); and several other notables in the field. It
s important to note the diversity of the fields
epresented by the members of the Board. They
ere not all physicians; they were not all
adiologists, cardiologists, or neurologists; they
ere not all spectroscopists, physicists, or engi-
eers. They represented scientists and physicians
panning virtually every aspect of magnetic
esonance.
The first job was to plan the first annual
eeting. It took place in Boston. We planned for
n attendance of 250 but, by the end of the first
ay of the meeting, the room at the Park Plaza
otel had to be expanded to accommodate more
han 800 attendees. Subsequently, the annual
eetings increased in attendance and were an
mportant source for support and growth of the
ociety. What happened to the SMRM? After
lmost 10 years of existence, it merged with the
ewer and considerably smaller Society com-
rised largely of radiologists—SMRM; its name
as changed to ISMRM and its multidisciplinary
omposition diminished.
he Society of Cardiovascular Magnetic Reso-
ance. There was so much potential for the appli-
ation of MR approaches to the cardiovascular
ystem that I organized several annual meetings
ponsored by the American Heart Association in
ollaboration with Charlie Higgins, MD, a pioneer
n cardiovascular radiology at the University of
alifornia at San Francisco. These meetings be-
ame increasingly more popular and after several
ears I brought up the concept of establishing
nother Society focused on cardiovascular magnetic
esonance. The response was mixed. Some were
ery much against it, but the majority was for it.
rofessor Donald Longmore, MD, a highly re-
pected surgeon and MRI physician from the Royal
rompton Hospital in London was the most sup-
ortive. Accordingly, we proceeded to organize a
ew Society similar to the way in which we had
rganized the original SMRM. We developed a
oard, an Executive Committee, a Journal (the
ournal of Cardiovascular Magnetic Resonance, or
CMR), an annual meeting and several committees.
hat Society is growing and has been instrumental
n providing an educational and scientific mission.
t has an annual meeting every winter and it is truly Cnternational. It has chapters in most continents
ncluding the latest chapter in Latin America.
lthough there aren’t any Nobel Laureates in key
ociety positions yet, Mansfield, Lauterbur and
rnst have been honorary members of the editorial
oard of the JCMR.
onclusions
here have been many changes since those early
ays. The old and remarkable SMRM is now the
SMRM. It remains an excellent society. Yet
othing could replace the excitement and enthu-
iasm observed at the meetings of the more
isciplinarily diverse SMRM with so many pio-
eers in attendance. Cardiovascular imaging has
ubstantially progressed. Echocardiography and
uclear cardiology remain the basics of cardiac
maging and can be found in many cardiologists’
ffices. Some larger practices have computed
omography angiographic equipment and others
ven have CMR. Since 1986, the official name for
he discipline has become MRI rather than the
ore precise NMR imaging. In fact, NMR is no
onger used in the context of imaging. Why was
he name changed? It was supposed to be
hanged to prevent lay people from being con-
erned that they were being exposed to a nuclear
rocess during their imaging study. Yet, patients
on’t generally complain when they undergo a
uclear medicine study. Nevertheless, even the
003 Nobel Committee used the term CMR.
agnetic field strength for cardiovascular imag-
ng has increased from 0.1 to 0.2T to 1.5T, and
ome are using platforms of 3.0T. Magnets are
ow being built for commercial use at field
trengths as high as 7.0T. CMR continues to
volve technically while the other imaging tech-
ologies are changing at a slower pace. Like
chocardiography, CMR has no ionization prop-
rties. Contrast agents generally are safe, with the
xception of studies in patients with end-stage
enal disease and new contrast agents are being
eveloped as nanotechnology and molecular im-
ging approaches continue to develop. In fact,
any of us believe that CMR will ultimately
rovide the “one-stop-shop” for cardiovascular
maging.
eprint requests and correspondence: Dr. Gerald M. Po-
ost, 9777 Wilshire Boulevard, 4th Floor, Beverly Hills,
alifornia 90212. E-mail: gerry2710@yahoo.com.
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